Zhang Weidong, Chen Zhuang, Li Fang, Kamencic Huse, Juurlink Bernie, Gordon John R, Xiang Jim
Department of Oncology, Research Unit, Saskatchewan Cancer Agency, University of Saskatchewan, Saskatoon, Saskatchewan, Canada S7N 0W0.
Immunology. 2003 Feb;108(2):177-88. doi: 10.1046/j.1365-2567.2003.01489.x.
Tumour antigen presentation by dendritic cells (DCs) to T cells in lymphoid organs is crucial for induction of anti-tumour immune responses. It has been previously reported that tumour necrosis factor-alpha (TNF-alpha) is required for DC activation and subsequent induction of optimal immune responses, and thus DCs for anti-tumour vaccination are often generated by culture in exogenous TNF-alpha. In the present study, we investigated the effect on anti-tumour immunity of vaccination with Mut1 tumour peptide-pulsed DCs engineered to express a TNF-alpha transgene. Our data shows that transfection of DCs with recombinant adenovirus AdV-TNF-alpha resulted in greater maturation of the DCs than occurred with control DCs cultured in exogenous TNF-alpha, as determined by up-regulated expression of pro-inflammatory cytokines (e.g. interleukins 1beta and 18), chemokines [e.g. interferon-gamma-inducible protein-10 and macrophage inflammatory protein-1beta (MIP-1beta)], the CC chemokine receptor CCR7, and immunologically important cell surface molecules (CD40, CD86 and intercellular adhesion molecule-1). These transgenic DCs stimulated stronger allogeneic T-cell responses in vitro and T-cell activation in vivo; displayed 2.4-fold enhanced chemotactic responses to the MIP-3betain vitro (P<0.05); and, perhaps most importantly, trafficked into the draining lymph nodes dramatically (seven-fold, P<0.01) more efficiently than the control DCs. Our data also demonstrate that vaccination of mice with Mut1 peptide-pulsed, AdV-TNF-alpha-transfected DCs stimulated more efficient in vitro Mut1-specific CD8+ cytotoxic T-cell responses and solid tumour immunity in vivo, when compared to the in vitro TNF-alpha-cultivated DCs. Thus, DCs engineered to secrete TNF-alpha may offer a new strategy in DC cancer vaccines.
树突状细胞(DCs)在淋巴器官中将肿瘤抗原呈递给T细胞对于诱导抗肿瘤免疫反应至关重要。先前已有报道称,肿瘤坏死因子-α(TNF-α)是DC激活及随后诱导最佳免疫反应所必需的,因此用于抗肿瘤疫苗接种的DCs通常通过在外源性TNF-α中培养来产生。在本研究中,我们调查了用经基因工程改造以表达TNF-α转基因的Mut1肿瘤肽脉冲DCs进行疫苗接种对抗肿瘤免疫的影响。我们的数据表明,用重组腺病毒AdV-TNF-α转染DCs导致DCs比在外源性TNF-α中培养的对照DCs成熟度更高,这是通过促炎细胞因子(如白细胞介素1β和18)、趋化因子[如干扰素-γ诱导蛋白-10和巨噬细胞炎性蛋白-1β(MIP-1β)]、CC趋化因子受体CCR7以及免疫重要细胞表面分子(CD40、CD86和细胞间黏附分子-1)表达上调来确定的。这些转基因DCs在体外刺激更强的同种异体T细胞反应和体内T细胞激活;在体外对MIP-3β显示出增强2.4倍的趋化反应(P<0.05);而且,也许最重要的是,与对照DCs相比,其进入引流淋巴结的效率显著提高(提高7倍,P<0.01)。我们的数据还表明,与体外TNF-α培养的DCs相比,用Mut1肽脉冲、AdV-TNF-α转染的DCs对小鼠进行疫苗接种在体外刺激更有效的Mut1特异性CD8+细胞毒性T细胞反应,并在体内刺激实体瘤免疫。因此,经基因工程改造以分泌TNF-α的DCs可能为DC癌症疫苗提供一种新策略。